Introduction
Peripheral cytopenias, such as anemia, auto-immune hemolysis, leukopenia, lymphopenia and thrombocytopenia are common in systemic lupus erythematosus (SLE). 1 These abnormalities are among the criteria for SLE in the revised American College of Rheumatology (ACR) 2, 3 and in the Systemic Lupus International
Collaborative Clinics (SLICC) 4 classifications and may be the first symptom of the disease. Besides these peripheral manifestations, bone marrow (BM) abnormalities, such as myelofibrosis, pure red cell aplasia (PRCA), aplastic anemia (AA) and features suggestive of myelodysplastic syndromes have been reported in patients with SLE, suggesting that the BM may also be a target organ in the disease. 5, 6 These hematologic disorders can lead to life-threatening BM failure. Reports of a relationship between disease control and improvement of cytopenia suggests a causal relationship between SLE and BM failure. [7] [8] [9] However, whereas the link between PRCA and SLE is well recognized, it is less clear for myelofibrosis and other BM manifestations.
Since BM involvement in SLE has not been thoroughly studied up to now, we report here the first results of a French registry of cases of BM abnormality associated with SLE.
Patients and methods

Patients
The French registry of 'lupus marrows' is a nationwide retrospective and prospective study that was initiated in July 2012 to describe the disease characteristics and treatment efficacy in patients presenting SLE with BM involvement. Inclusion criteria were: (i) a diagnosis of SLE according to the SLICC criteria, 4 (ii) a cyto-histopathologic analysis revealing significant BM abnormalities and (iii) the exclusion of other possible causes of marrow failure, such as erythrovirus B19 infection and iatrogenic factors. French internal medicine, nephrology, rheumatology and hematology units were invited to take part in the registry. Three patients (cases 8, 10 and 27) have been previously discussed in literature reviews. 5, 6 Data Using a standardized form, clinical and laboratory data were recorded for each patient at the time of SLE diagnosis, at the onset of BM involvement and during follow-up, by the practitioners in charge of the patients. Anemia was defined as a hemoglobin level below 12 g/dl, leukopenia as a white blood count (WBC) below 4 x10 9 /l, thrombocytopenia as a platelet count below 150 x10 9 /l, lymphopenia as a lymphocyte count below 1 x 10 9 /l and neutropenia as a neutrophil count below 1.5 x 10 9 /l. BM aspirations and/or biopsies were transferred for centralized review whenever possible.
The study was performed in accordance with the ethical standards of the Helsinki Declaration and was approved by the local institutional review board.
Statistical analysis
The data were described as numbers and percentages for qualitative variables and medians or means and ranges for quantitative variables.
Results
Clinical history
Initially, 37 patients were considered for inclusion. Six of these patients did not fulfil inclusion/exclusion criteria (SLE criteria not met in two cases, BM normal in two cases, BM aspiration or biopsy not performed in one case, and marrow failure clearly of iatrogenic origin in one case) and one was excluded owing to insufficient data. Finally, 30 patients hospitalized from 1998 to 2014 in 19 centers were included. Central hematologic manifestations of SLE consisted in BM fibrosis (n ¼ 17; 57%), PRCA (n ¼ 8; 27%), myelodysplastic syndrome (n ¼ 3; 10%), AA and agranulocytosis (n ¼ 1; 3% each). Three of the 30 patients included were male and 27 female, giving a sex ratio of 1:10. Their median age was 36 years [range: 18-71 years] at the time of BM involvement. BM involvement was either diagnosed concomitantly with SLE (n ¼ 12) or detected in patients who had already been diagnosed with SLE (n ¼ 18) a median of 7 years [1-20 years] previously. Thirteen patients presented prior cytopenia with no specific diagnosis: anemia (n ¼ 10), lymphopenia (n ¼ 10), neutropenia (n ¼ 4) and thrombocytopenia (n ¼ 4).
SLE at the time of BM involvement
Concomitant SLE manifestations were articular (43%), cutaneous (43%), renal (37%), serous (17%) and neurological (13%) ( Table 1) . Complement level was often low (20 patients out of 28 tested). Antinuclear antibodies (ANA) were found in all patients, and anti-dsDNA antibodies in 25 patients. Anti-SSA antibodies were found in 13 patients, anti-RNP in 8, anti-Sm in 7, anti-SSB, anti-ribosome, anti-Scl70 and rheumatoid factor in 2 patients each, and anti-chromatin, anti-histone, anti-nucleosome and anti-CCP in 1 patient each. Antiphospholipid antibodies were present in 10 patients. Anti-platelet antibody tests were positive in three patients and negative in four, an anti-granulocyte antibody test being negative in the only patient tested (Supplementary material).
Regarding the 18 patients with previously diagnosed SLE, treatment at the onset of hematologic complications included corticosteroids (n ¼ 10), hydroxychloroquine (n ¼ 7), mycophenolate mofetil (n ¼ 2), azathioprine (n ¼ 1) and cyclophosphamide (n ¼ 1) (Supplementary material).
Hematologic symptoms at the time of BM involvement
Splenomegaly was found in 6 patients (5/17 with BM fibrosis), hepatomegaly in 5 patients (with a biopsy in one case showing myeloid metaplasia) and lymph node enlargement in 13 patients (biopsy in one case showing myeloid metaplasia too). The other main symptoms reported were fever (47%) and bleeding (17%) (Supplementary material). 
Neurologic
Bone marrow fibrosis Fourteen of the 30 patients (47%) presented pancytopenia, 7 (23%) bicytopenia (anemia and/or leukopenia and/or thrombocytopenia) and 9 (30%) only one form of cytopenia. The mean leukocyte count was 3.7 x 10 9 /l [0. Tear-drop cells or leukoerythroblastic blood smears were documented in two patients. Whenever evaluated, levels of folate and vitamin B12 were normal. Ferritin levels were normal or increased.
With the exception of one patient (in whom fibrosis was diagnosed on the basis of marrow biopsy alone), all patients underwent BM aspiration. This contributed to diagnosis in 18 cases (Supplementary material). Twenty-two patients had a BM biopsy which contributed to diagnosis in 21 cases (Supplementary material). In the eight patients with no biopsy, the diagnosis (PRCA in five patients and myelodysplastic syndrome in three) was based on BM aspiration. BM biopsies and/or aspirations were reviewed centrally for 24 patients (if this was not possible, the results of the local examination was reported in the tables included in the Supplementary material).
Histologic examination ( Figure 1 ) showed BM fibrosis in 19 patients, including one case of PRCA and one case of agranulocytosis with variable increases in the amount of reticulin fibers (grade 1-3). Global cellularity, interpretable in 21 biopsies, was variable, ranging from increased in 6 patients to normal in 13 and decreased in 2. One case of suspected increase in blasts was not confirmed by the centralized review. Erythropoiesis abnormalities were noted in 27 patients, granulopoiesis abnormalities in 16 patients and megakaryopoiesis abnormalities in 8 patients (17 patients presented thrombocytopenia). Lymphocytic infiltration was observed in 10 patients, and plasmocytosis in 18 patients. Macrophages with debris and/or pigments in their cytoplasm were observed in 13 cases and sinusoidal dilatation in 2 cases. Erythrophagocytosis not meeting the criteria for hemophagocytic activation syndrome was identified in six cases (including one case identified later on centralized review), including two BM fibrosis, two PRCA and two dysmyelopoietic syndrome. We noted that all these patients had a lymph node hyperplasia (lymph node enlargement and/or splenomegaly and/or hepatomegaly). It seems that they had more severe cytopenias (Supplementary material) but there was no difference in the prognosis and response to treatment compared to the rest of the cohort.
BM necrosis was never observed. JAK-2 mutation was screened in one patient and proved negative. MPL W515L/K and calreticulin mutations were never checked. Extramedullary hematopoiesis detectable in hepatic or lymph node biopsies was reported in two cases. One patient underwent indium scintigraphy, leading to the diagnosis of splenic myeloid metaplasia.
Finally, six patients underwent a second BM examination. Five of these control analyses were prompted by persistent clinical and/or biological abnormalities, and confirmed relapse or the absence of improvement, and one by an increase in blast count (not confirmed by centralized review), showing improvement.
Treatments and outcome
Therapies consisted in corticosteroids (n ¼ 27), hydroxychloroquine (n ¼ 26), rituximab (n ¼ 10), intravenous immunoglobulins (n ¼ 9), mycophenolate mofetil (n ¼ 6), ciclosporine (n ¼ 6), cyclophosphamide (n ¼ 3), azathioprine (n ¼ 2), methotrexate, tacrolimus, danazol and purinethol, antithymocyte globulin, and allogeneic hematopoietic stem cell transplant (n ¼ 1 each). One asymptomatic patient with mild cytopenias received no specific treatment. We could not identify any specific use of a particular treatment for a particular type of complication. Details of treatment according to hematologic complication are provided in Table 2 .
Among the 27 patients treated with steroids, 5 patients received only steroids (6hydroxychloroquine) and improved in the long term. Nine other patients were steroid-dependent.
Two patients received granulocyte colony stimulating factor (G-CSF) and six received erythropoietin. Supportive care including blood transfusions was required for 14 patients, platelet transfusion for 3 and antibiotics for 12 patients.
The mean follow-up was 27 months [1-142 months]. Improvement with the first treatment was noted in 14 patients (47%), transient response with the need for new treatments in 10 (33%) and no improvement or relapse in 6 (20%) ( Table 2 ). The mean interval between treatment and resolution of hematologic complications was 9 months [1-75] among the 24 responders. At the end of follow-up, all patients were alive. Nineteen were on hydroxychloroquine (including 15 on hydroxychloroquine only), 14 were on steroids and 8 on immunosuppressive drugs. Table 3 summarizes patient characteristics according to the type of BM involvement.
Discussion
We report for the first time a large series of 30 SLE patients included in the French multicenter registry of 'lupus marrows'. Central hematologic manifestations consisted in BM fibrosis (57%), PRCA (27%), myelodysplastic syndrome (10%), AA and agranulocytosis (3% each). Since BM involvement in SLE patients has only recently been recognized as a rare, but real complication of SLE, 5, 6 and since only case-reports and reviews have been published to date, the aim of our series was to further the understanding and management of these SLE manifestations. The diagnosis of SLE was robust for all the patients (at least four SLE classification criteria). The characteristics of the patient population, especially the sex ratio, the mean age at SLE diagnosis, and the rates of renal involvement and neurological manifestations were in keeping with those usually observed in SLE. 10, 11 Central hematologic manifestations were either inaugural or occurred in patients with known SLE to a similar extent. Concomitant clinical symptoms of SLE at the time of hematologic complications were frequent in patients presenting BM fibrosis, but were seldom seen in patients manifesting PRCA, corroborating previous observations. 6, 12 Cytopenias were often present several months before diagnosis of BM involvement, the time to this diagnosis confirming the need for more systematic BM evaluation in such patients. Discontinuation of drugs potentially inducing BM failure should not delay further evaluation and management of patients. A strength of our study was the centralized review of BM samples, which showed that the interpretation of BM aspirations and biopsies is sometimes complex. Aspirations alone were often insufficient and biopsies were necessary to make the diagnosis. Global marrow cellularity was difficult to evaluate owing to the lack of a standardized classification for aspirations, although BM abnormalities have already been described in SLE. 13 Interestingly, the main central hematologic manifestation was BM fibrosis, observed in 17 patients. The term 'myelofibrosis' encompasses myelofibrosis associated with infections, neoplasms and autoimmune diseases, as well as primary myelofibrosis, a clonal myeloproliferative disorder.
14 Cases of BM fibrosis have been reported in patients with well-defined autoimmune syndromes and it is likely that 'autoimmune myelofibrosis', may occur either as an isolated disorder, or as a feature of other autoimmune diseases, including SLE. 15, 16 In contrast to our review of the literature, indicating a bleeding rate of 58%, only 18% of our patients with BM fibrosis presented signs of bleeding (Table 3) . 6 This difference may be explained by reporting bias, case reports tending to document more severe cases. Like primary myelofibrosis, autoimmune BM fibrosis can be associated with constitutional symptoms (fever and asthenia) and splenomegaly (30% of our patients) ( Table 3 ). 14 However, SLE BM fibrosis differed from primary myelofibrosis in that our SLE patients were younger than those with primary myelofibrosis, with a median age of 36 years vs. 65 years 14 and were more frequently female. Furthermore, associated extra-hematologic autoimmune symptoms were frequent, levels of circulating blasts did not exceed 1% (whereas levels >1% are seen in more than half the primary myelofibrosis), collagen fibrosis was absent and, more importantly, improvement with treatment was frequently observed, even with high-dose corticosteroids alone. 6 In keeping with this finding, repeated biopsies showed an improvement of reticulin fibrosis after treatment of patients for the underlying autoimmune disease. 15 We were not able to confirm that absence of the JAK2 V617F mutation argues for autoimmune BM fibrosis, since only one patient in our series was tested with a negative result. 17 The second most common central hematologic manifestation was PRCA, presented by eight patients. Only three of the eight patients presented clinical symptoms of SLE. However, all eight patients displayed biological signs of SLE, with lymphopenia, positive anti-DNA antibodies and low complement levels at the time of the hematologic complication. Histologic examination showed BM fibrosis in one patient with PRCA, an association already known. 18 The response to treatment was good.
More than 30 cases of PRCA in SLE patients have been reported in the literature, 12 their autoimmune nature being widely recognized. The causal relationship between these conditions and SLE is less controversial than that between myelofibrosis and SLE.
Other central hematologic manifestations of SLE were particularly rare. For example, our registry included only three cases of myelodysplastic syndrome in SLE, in accordance with its rarity in the literature, only a few case reports having been published. 19 However, myelodysplastic features often accompanied BM fibrosis in our patients. These features, like those of fibrosis, seem to be more prevalent than previously thought and, just as BM fibrosis associated with SLE differs from primary myelofibrosis, myelodysplastic features related to SLE have to be distinct from clonal myelodysplastic syndrome features. Whenever investigated, chromosomal and molecular abnormalities were absent in our patients. Like BM fibrosis, myelodysplastic features could regress with treatment. 19 The term 'dysmyelopoietic' is probably more appropriate than myelodysplastic for SLE patients, just as BM fibrosis is more appropriate than myelofibrosis, because the latter terms refer to clonal disorders. Only one case of AA is included in our registry. This may reflect the extreme rarity of this complication, even though it has already been described, 5 or selection bias, AA generally being treated in a hematologic unit (only one such center participating). Evaluation of the efficacy and safety of different therapeutic regimens was a major goal in our registry. However, the heterogeneity of the treatments used makes it difficult to draw any firm conclusions, except that treatment of the underlying disease, i.e. SLE, was usually effective. High doses of steroids alone were effective in 5/27 patients. Other treatment options include intravenous immune globulins, plasma exchanges, rituximab and other immunosuppressive agents. This study provides additional information on the use of rituximab and intravenous immunoglobulins. In keeping with case reports, 7,19 a response was reported in 67% of patients who received rituximab as first or second-line treatment, supporting its use in naive or relapsing/ refractory patients. Immunoglobulins that are effective in patients with peripheral thrombocytopenia associated with SLE achieved response in two patients with BM fibrosis and in 5/6 patients with PRCA. The use of immunoglobulins has been reported in several patients with PRCA, and also in some patients with AA or fibrosis. 5, 6 Erythropoietin seems to be effective against anemia (3/5). 20 Only one patient needed an allogeneic hematopoietic stem cell transplant. The use of eltrombopag in AA has already been validated. 21 All these treatments were well tolerated. Finally, except for corticosteroids, no single approach appeared to be significantly more effective than others according to the type of BM involvement (Table 3) . After a median follow-up of 27 months, all the patients were alive and 24 had no evidence of active BM involvement. So the prognosis appears to be better than for patients with primary myelofibrosis and also better than previously thought. 5, 6 The pathogenesis of BM involvement remains for the most part unexplained, but immunological processes are likely to be involved. An increase in leukocyte apoptosis and an impaired clearance of apoptotic cells have been observed in SLE. These apoptotic bodies were observed in the BM of patients with SLE, whereas they are not typically seen in normal BM. Inefficient apoptotic cell clearance leads to prolonged exposure to autoantigens and predisposes patients to antibody production and SLE. 22 It has also been suggested that abnormal T cells may dysregulate hematopoiesis through an abnormal cytokine network and may initiate and perpetuate damage to the BM. Median delay between SLE and complication (years)
Furthermore, autoantibodies that inhibited in vitro BM colony formation from granulocyte-macrophage progenitor cells and blast-forming units-erythroid have been detected in sera and their activity and number decreased with successful immunosuppressive therapy. 24 Our study has some limitations, due to its retrospective design and to the rarity of BM involvement in SLE, which reduced the power of the analyses. In particular, the heterogeneity of the treatments used made it difficult to issue any strong therapeutic recommendation.
Conclusion
This registry describes the presentation, prognosis and therapeutic management of the largest series of patients with SLE presenting BM involvement. BM fibrosis was the most frequent hematologic manifestation, was often associated with active SLE and responded well to SLE treatment, all these findings providing evidence for a strong link between SLE and BM fibrosis, which is likely to be of autoimmune origin. BM involvement may be more common than previously thought, with cases being incorrectly characterized as peripheral cytopenias in patients previously diagnosed with SLE, and cases being misdiagnosed as primary BM failure in patients not previously diagnosed with SLE. Accordingly, cytopenia in SLE should lead to BM examination in atypical or refractory cases. Moreover, SLE-associated BM fibrosis should be considered in cases of primary myelofibrosis with atypical features such as young age, female sex, absence of blasts or collagen fibers because this condition seems amenable to effective treatment. The longterm prognosis of SLE patients with BM involvement does not appear to be as poor as previously reported.
